PTMA gene is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-07-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Acetylated peptide | N-terminal acetyl group blocks aminopeptidase attack |
| Residue count | 28 amino acids | Matches the N-terminus of prothymosin alpha |
| Molecular mass | About 3,108 Da | Value for the free, unmodified peptide |
| Isoelectric point | Approximately 4.2 | Acidic; net negative charge at neutral pH |
| Encoding gene | PTMA | Human gene for the precursor protein |
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
The location of the enzyme that links these two parts of gluconeogenesis by converting oxaloacetate to PEP – PEP carboxykinase (PEPCK) – is variable by species: it can be found entirely within the mitochondria, entirely within the cytosol, or dispersed evenly between the two, as it is in humans. Transport of PEP across the mitochondrial membrane is accomplished by dedicated transport proteins; however no such proteins exist for oxaloacetate. Therefore, in species that lack intra-mitochondrial PEPCK, oxaloacetate must be converted into malate or aspartate, exported from the mitochondrion, and converted back into oxaloacetate in order to allow gluconeogenesis to continue.
f is a factor which depends on the volumes of the two phases. Thus, the higher the affinity of the solute for the stationary phase, the slower the migration rate. There is a wide variety of chromatographic techniques, depending on the nature of the stationary and mobile phases. When the stationary phase is solid, the analyte may form a complex with it. A water softener functions by selective complexation with a sulfonate ion exchange resin. Sodium ions form relatively weak complexes with the resin. When hard water is passed through the resin, the divalent ions of magnesium and calcium displace the sodium ions and are retained on the resin, R.
0–6 months: 25 μg/d (1000 IU/d) 7–12 months: 38 μg/d (1500 IU/d) 1–3 years: 63 μg/d (2500 IU/d) 4–8 years: 75 μg/d (3000 IU/d) 9+ years: 100 μg/d (4000 IU/d) Pregnant and lactating: 100 μg/d (4000 IU/d) Although in the US the adult UL is set at 4,000 IU/day, over-the-counter products are available at 5,000, 10,000 and even 50,000 IU (the last with directions to take once a week). The percentage of the US population taking over 4,000 IU/day has increased since 1999.
=== B cells === TGF-β1 has similar effects on B cells that also vary according to the differentiation state of the cell. It inhibits proliferation, stimulates apoptosis of B cells, and controls the expression of antibody, transferrin and MHC class II proteins on immature and mature B cells.
Sources: en.wikipedia.org
== Environmental impact and waste management == The global cheese industry generates approximately 160 million cubic meters of whey annually. While a significant portion is processed into value-added products, roughly 42% of this volume remains unutilized, often being used as low-value animal feed, fertilizer, or discharged directly into water bodies. Due to its high organic load (50–80 g COD/L) and nutrient content (nitrogen and phosphorus), improper disposal of whey poses a significant risk of eutrophication in aquatic ecosystems.
Angiogenin (ANG) also known as ribonuclease 5 is a small 123 amino acid protein that in humans is encoded by the ANG gene. Angiogenin is a potent stimulator of new blood vessels through the process of angiogenesis. Ang hydrolyzes cellular RNA, resulting in modulated levels of protein synthesis and interacts with DNA causing a promoter-like increase in the expression of rRNA. Ang is associated with cancer and neurological disease through angiogenesis and through activating gene expression that suppresses apoptosis.
The two substrates of this enzyme are (+)-borneol and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are (+)-camphor, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is (+)-borneol:NAD+ oxidoreductase. This enzyme is also called bicyclic monoterpenol dehydrogenase.
== Spectrum of activity == Tylosin has a wide spectrum of activity against Gram-positive bacteria including Staphylococcus, Streptococcus, Corynebacterium, and Erysipelothrix. It has a much narrower Gram-negative spectrum of activity, but has been shown to be active against Campylobacter coli, and certain spirochaetes. It has also been shown to be extremely active against Mycoplasma species isolated from both mammalian and avian hosts. The following represents MIC susceptibility data for a few medically significant pathogens:
== Nutritional aspects == Significant elements of the nutritional science of fish protein powders centers around the bioactive and antioxidant properties of the peptide fractions produced during hydrolysis and their ability to have a positive impact on many conditions including gastrointestinal issues associated with irritable bowel syndrome (IBS) and Crohn's disease - as well reduction effects on hypertension and fast absorption functionality promotes the addition of lean muscle mass to humans consuming the products. Further studies showed that peptides in fish protein powders can minimize injurious effects of anti-inflammatory pain drugs. The University of Maryland School of Medicine concluded that certain peptide fractions from fish may inhibit prostate cancer and possibly other cancers from spreading. Additional benefits of fish protein powders are centered around diet needs of various subsets of the human population. Individuals who have lactose intolerance, milk allergy, gluten intolerance or coeliac disease (aka Celiac's) require alternate protein sources. The hydrolyzed nature of fish protein powder (low molecular weight profile) leads it to be used in hypoallergenic applications such as infant formulas. There is no evidence that infants who have a high risk of having an allergy to cows milk should be fed hydrolyzed infant formula instead of breast milk for allergy prevention.
Sources: en.wikipedia.org
Whether that ever means we'll ever play live again, I don't know, especially after Robert's recent [heart attack]." He confirmed that the new album would feature the studio versions of new songs performed by the band between 2014 and 2021, and that "some other bits and pieces will emerge from putting it together. I think so." This news suggests that despite Fripp's 2021 announcement, King Crimson may still be active (albeit as a studio project). In a DGM homepage and Facebook post on 11 July 2025, while suggesting the possibility of "an album the very sound of which no-one has ever heard before. A sound driven by the three drummers," David Singleton both clarified and cautioned speculation about the album. He commented that "it is true that [the three] drummers have now recorded studio versions of their parts – separately, so that there is perfect separation. So there is indeed the seed of a new recording. Whether it is an album, whether it sees the light of day, whether it is something else is unknown. As is the outcome of any creative process. So yes, recordings have taken place. We are building a new studio, and when it is complete I am looking forward to seeing what may, or may not, exist. Getting excited about the possibility of a new album, as has been happening in some quarters, is however somewhat premature. Carts before horses." In a May 2026 interview, Fripp stated that the rumoured new album never came to fruition, that he would not play live again, and that King Crimson's career was over for good.
== Committees of the People's Assembly == Within the People's Assembly, there are several committees responsible for discussing and approving legislation proposed by the People's Assembly regarding a specific field related to these committees. These committees were formed by a 17-member special committee formed by People's Assembly speaker Abdul Hamid al-Awak, and is responsible with drafting laws regarding the internal regulations of the People's Assembly, such as the formation and election of committees, and holding sessions of the People's Assembly. In total, there are currently 26 committees of the People's Assembly; these committees were formed on 30 July 2026, after the second session of the 22nd People's Assembly.
Felinine, also known as (R)-2-amino-3-(4-hydroxy-2-methylbutan-2-ylthio)propanoic acid, is an amino acid found in cat urine and a precursor via microbial lyase of the putative cat pheromone and thiol called 3-mercapto-3-methylbutan-1-ol (MMB).
==== Total synthesis ==== The first structure elucidation and total synthesis of the cocaine molecule was accomplished by Richard Willstätter in 1898. Willstätter's synthesis involved constructing the cocaine structure from simpler precursors, notably via the intermediate tropinone. Subsequent significant contributions to understanding the synthetic pathway and stereochemistry were made by Robert Robinson and Edward Leete. Cocaine contains four chiral centers (1R, 2R, 3S, and 5S), two of which are configurationally dependent, resulting in eight possible stereoisomers. The formation of inactive stereoisomers, along with various synthetic by-products, limits both the yield and purity of the final product. Although the chemical synthesis of cocaine is technically feasible, it remains impractical due to its high cost, low efficiency, and complex stereoselective synthesis compared to extraction from natural plant sources. While domestic clandestine laboratories could theoretically reduce reliance on offshore production and international smuggling—as seen with illicit methamphetamine—manufacture and synthetic production of cocaine remains rare. Large-scale commercial synthesis has not been explored.
=== Composition === The Composition C-4 used by the United States Armed Forces contains 91% RDX ("Research Department Explosive", an explosive nitroamine), bound by a mixture of 5.3% dioctyl sebacate (DOS) or dioctyl adipate (DOA) as the plasticizer (to increase the plasticity of the explosive), thickened with 2.1% polyisobutylene (PIB, a synthetic rubber) as the binder, and 1.6% of a mineral oil often called "process oil". Instead of "process oil", low-viscosity motor oil is used in the manufacture of C-4 for civilian use. The British PE4 consists of 88.0% RDX, 1.0% pentaerythrite dioleate and 11.0% DG-29 lithium grease (corresp. to 2.2% lithium stearate and 8.8% mineral oil BP) as the binder; a taggant (2,3-dimethyl-2,3-dinitrobutane, DMDNB) is added at a minimum of 0.10% weight of the plastic explosive, typically at 1.0% mass. The newer PE7 consists of 88.0% RDX, 1.0% DMDNB taggant and 11.0% of a binder composed of low molecular mass hydroxyl-terminated polybutadiene, along with an antioxidant and an agent preventing hardening of the binder upon prolonged storage. The PE8 consists of 86.5% RDX, 1.0% DMDNB taggant and 12.5% of a binder composed of di(2-ethylhexyl) sebacate thickened with high molecular mass polyisobutylene. Technical data according to the Department of the Army for the Composition C-4 follows.
Sources: en.wikipedia.org
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.
The precursor, prothymosin alpha, is encoded by the PTMA gene in humans. The 28-residue peptide corresponds to the N-terminal segment released from that larger protein.
It is produced as a fragment of prothymosin alpha and is present in many tissues. Circulating concentrations are low, which makes routine measurement difficult.
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.